ATB-338

ATB-338 is an early-stage investigational drug candidate developed by AltiBio, a biopharmaceutical company founded by former executives of Raptor Pharmaceuticals. Identified in late 2018 following a Series A financing round, ATB-338 is part of a pipeline focused on treating undisclosed rare diseases. The drug has completed preclinical proof-of-concept studies and has undergone initial formulation development. While AltiBio's broader platform focuses on first-in-class biologics designed to modulate the immune system—specifically through the depletion of pathogenic T cells—the precise molecular target, mechanism of action, and primary clinical indication for ATB-338 remain proprietary and have not been disclosed in public clinical registries or scientific literature.